ReviewDigestive diseases and sciences2008
Inflammation and repair in viral hepatitis C.
Review in Digestive diseases and sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Alcohol Use and the Risk of Communicable Diseases.Nutrients · 2021Review
- Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization.Journal of clinical and translational hepatology · 2018Article
- Current progress in host innate and adaptive immunity against hepatitis C virus infection.Hepatology international · 2017Review
- Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.Alimentary pharmacology & therapeutics · 2015Article
- Autoimmune reactions in the course of the hepatitis C virus (HCV) infection.Clinical and experimental hepatology · 2015Review
- Specific oligopeptides in fermented soybean extract inhibit NF-κB-dependent iNOS and cytokine induction by toll-like receptor ligands.Journal of medicinal food · 2014Article
- Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems.AIDS (London, England) · 2014Article
- Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems.Addiction (Abingdon, England) · 2014Article
- Immune activation in HIV/HCV-infected patients is associated with low-level expression of liver expressed antimicrobial peptide-2 (LEAP-2).Journal of clinical pathology · 2013Article
- Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems.AIDS research and human retroviruses · 2013Article
- Hepatic stimulator substance alleviates toxin-induced and immune-mediated liver injury and fibrosis in rats.Digestive diseases and sciences · 2012Article
- Microbial translocation across the GI tract.Annual review of immunology · 2012Review
- Pegylated interferon de novo-induce autoimmune haemolytic anaemia in chronic hepatitis C patient.BMJ case reports · 2011Article
- New insights into the role of macrophages in adipose tissue inflammation and Fatty liver disease: modulation by endogenous omega-3 Fatty Acid-derived lipid mediators.Frontiers in immunology · 2011Article
- Molecular and contextual markers of hepatitis C virus and drug abuse.Molecular diagnosis & therapy · 2009Review
- Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012.Alcohol and alcoholism (Oxford, Oxfordshire)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 11 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C viral infection (HCV) results in liver damage leading to inflammation and fibrosis of the liver and increasing rates of hepatic decompensation and hepatocellular carcinoma (HCC). However, the host's immune response and viral determinants of liver disease progression are poorly understood. This review will address the determinants of liver injury in chronic HCV infection and the risk factors leading to rapid disease progression. We aim to better understand the factors that distinguish a relatively benign course of HCV from one with progression to cirrhosis. We will accomplish this task by discussion of three topics: (1) the role of cytokines in the adaptive immune response against the HCV infection; (2) the progression of fibrosis; and (3) the risk factors of co-morbidity with alcohol and human immunodeficiency virus (HIV) in HCV-infected individuals. Despite recent improvements in treating HCV infection using pegylated interferon alpha (PEGIFN-alpha) and ribavirin, about half of individuals infected with some genotypes, for example genotypes 1 and 4, will not respond to treatment or cannot be treated because of contraindications. This review will also aim to describe the importance of IFN-alpha-based therapies in HCV infection, ways of monitoring them, and associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.